Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Going back to the $2.80 highs.....

<< Previous

Bullboard Posts

Next >>

Comment by GJS471on Feb 16, 2022 2:48pm

202 Views

Post# 34434863

RE:RE:RE:RE:RE:Going back to the $2.80 highs.....

These are interesting times. I think this quarter will be a telling sign on pricing but with little information to back it up. The company is holding its cards close to the chest. I don't blame them but they treat it like a private company, As a shareholder it is very, very frustrating. For those in power, time to pull a rabbit out of the hat.

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload